Gain Therapeutics

Company snapshot

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plas

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 27 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Gain Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Gain Therapeutics.

1. Jun 8, 2026 Clinical update

   combined fixed dose combination — Approved

2. Jun 8, 2026 Clinical update

   Low Dose GT-02287 — Phase 2

3. Jun 8, 2026 Clinical update

   Envita Stories Methodology in Long-term care Centres for old adults — Unknown

4. Jun 5, 2026 Clinical update

   GT-02287 — Phase 1

5. Jul 29, 2025 Patent grant

   Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition

View all clinical trial activity →

• What is Gain Therapeutics?

  Gain Therapeutics is a pharma organization headquartered in Bethesda, USA. It trades on NYSE under ticker GANX. Primary therapeutic focus areas include Parkinson Disease, Tuberculosis, Long-term Care Centres for Old Adults Users. NovaPharmaNews links 4 clinical program(s), 0 drug

• Is Gain Therapeutics publicly traded?

  Yes. Gain Therapeutics is listed with ticker GANX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Gain Therapeutics develop or market?

  We link 7 drug profile(s) where Gain Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gain-therapeutics#company-drugs.

• What are the latest developments for Gain Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Gain Therapeutics focus on?

  Gain Therapeutics focuses on Parkinson Disease, Tuberculosis, Long-term Care Centres for Old Adults Users based on our analysis of their pipeline programs and drug development activities.